Literature DB >> 7061992

Studies on the mechanism of neutralization of influenza virus by antibody: evidence that neutralizing antibody (anti-haemagglutinin) inactivates influenza virus in vivo by inhibiting virion transcriptase activity.

R D Possee, G C Schild, N J Dimmock.   

Abstract

Influenza viruses, which had lost up to 99.999% infectivity by incubation with antibody (a) specific for the haemagglutinin (HA) or with monoclonal alpha-HA, attached on to and penetrated chick embryo fibroblast (CEF) cells to the same extent as non-neutralized virus. Neutralized virus was also uncoated efficiently as shown by the accumulation of virion RNA in the nucleus and virion envelope in the cytoplasm. Polyacrylamide gel electrophoresis of virion RNA segments recovered from the nucleus or cytoplasm of cells inoculated with neutralized or non-neutralized virus showed that antibody did not potentiate degradation of RNA. However, these RNAs were not expressed since virus-induced proteins were not detected in cells to which neutralized virus had been added. Assay of virion transcriptase of neutralized virus in vitro showed that its activity was reduced up to sevenfold compared with non-neutralized virus, and annealing studies showed that no detectable transcription took place in vivo with neutralized virus. These studies support the conclusion that antibody directed specifically against the HA protein on the outer surface of the influenza virus particle neutralizes infectivity by inactivating virion transcriptase activity and it is suggested that antibody to HA brings about allosteric rearrangements in the HA molecule which are transmitted across the virus envelope to the interior of the particle.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7061992     DOI: 10.1099/0022-1317-58-2-373

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  19 in total

1.  Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event.

Authors:  M J Edwards; N J Dimmock
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

Review 2.  Insights into neutralization of animal viruses gained from study of influenza virus.

Authors:  M C Outlaw; N J Dimmock
Journal:  Epidemiol Infect       Date:  1991-04       Impact factor: 2.451

3.  Antibodies to the trypsin cleavage peptide VP8 neutralize rotavirus by inhibiting binding of virions to target cells in culture.

Authors:  F M Ruggeri; H B Greenberg
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

4.  Alterations to influenza virus hemagglutinin cytoplasmic tail modulate virus infectivity.

Authors:  D A Simpson; R A Lamb
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

5.  Is bivalent binding of monoclonal antibodies to different antigenic areas on the hemagglutinin of influenza virus required for neutralization of viral infectivity?

Authors:  S Yoden; H Kida; R Yanagawa
Journal:  Arch Virol       Date:  1985       Impact factor: 2.574

6.  Neutralization of poliovirus by polyclonal antibodies requires binding of a single IgG molecule per virion.

Authors:  K Wetz; P Willingmann; H Zeichhardt; K O Habermehl
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

7.  The synergistic neutralization of Newcastle disease virus by two monoclonal antibodies to its haemagglutinin-neuraminidase protein.

Authors:  P H Russell
Journal:  Arch Virol       Date:  1986       Impact factor: 2.574

8.  Destabilization of herpes simplex virus type 1 virions by local anesthetics, alkaline pH, and calcium depletion.

Authors:  K Yanagi; S Harada
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

9.  Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms.

Authors:  C Wohlfart
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

10.  Enhanced protection against respiratory influenza A infection in mice by liposome-encapsulated antibody.

Authors:  J P Wong; L L Stadnyk; E G Saravolac
Journal:  Immunology       Date:  1994-02       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.